Although patients’ response to treatment depends on the presence of a particular biomarker, clinical outcome and cost-effectiveness of testing will differ because prognosis differs across tumor sites and even receptor types (TNBC and HR+/HER2- for breast cancer), health gains depend on prognosis, and the total testing costs of diagnosed patients depend on biomarker prevalence within tumor type. Here, ERBB2 is linked to breast cancer.